Singapore Clinical Trial: A Phase I/II open label study of DJI136, a DLL3-targeted CAR-T therapy, in adult patients with ES-SCLC

Singapore, Nov. 11 -- The Health Sciences Authority received information related to the study titled 'A Phase I/II open label study of DJI136, a DLL3-targeted CAR-T therapy, in adult patients with ES-... Read More

Singapore Clinical Trial: Beamion PANTUMOR 1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2 mutated or overexpressed/amplified solid tumours

Singapore, Nov. 11 -- The Health Sciences Authority received information related to the study titled 'Beamion PANTUMOR 1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficac... Read More

Singapore Clinical Trial: An open-label, multi-center, phase I/Ib study of IEV407 as a single agent and in combination with endocrine therapy in patients with advanced hormone receptor positive, HER2- negative breast cancer

Singapore, Nov. 11 -- The Health Sciences Authority received information related to the study titled 'An open-label, multi-center, phase I/Ib study of IEV407 as a single agent and in combination with ... Read More

Singapore Clinical Trial: A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (WHO Group 3)

Singapore, Nov. 11 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safet... Read More

Singapore Clinical Trial: DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLOZASIRAN IN ADULTS WITH SEVERE HYPERTRIGLYCERIDEMIA AT HIGH RISK OF ACUTE PANCREATITIS (SHASTA-5 STUDY)

Singapore, Nov. 11 -- The Health Sciences Authority received information related to the study titled 'DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLOZASIRAN ... Read More

Singapore Clinical Trial: Anti-CD7 Protein Expression Blocker (PEBL) Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia (CARTALL-2): A Phase 2 study

Singapore, Nov. 11 -- The Health Sciences Authority received information related to the study titled 'Anti-CD7 Protein Expression Blocker (PEBL) Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Rela... Read More

Singapore Clinical Trial: A Phase 1, Randomized, Placebo-Controlled, Single- and Multiple-Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4247147 in Participants with Obesity or Overweight who are Otherwise Healthy

Singapore, Nov. 11 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Randomized, Placebo-Controlled, Single- and Multiple-Ascending Dose Escalation Study to... Read More

Singapore Clinical Trial: A Phase II, Open-label Platform Study of Osimertinib in Combination with Anti-cancer Agents in Participants With EGFR-mutated Metastatic Non-small Cell Lung Cancer Whose Disease Has Progressed on Prior Osimertinib and Chemotherapy Combination Treatment (GROVE)

Singapore, Nov. 11 -- The Health Sciences Authority received information related to the study titled 'A Phase II, Open-label Platform Study of Osimertinib in Combination with Anti-cancer Agents in Par... Read More

Singapore Clinical Trial: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial To Evaluate The Efficacy And Safety Of Enicepatide In Participants With Overweight Or Obesity And Heart Failure With Reduced Ejection Fraction

Singapore, Nov. 11 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial To Evaluate The Efficacy And Safe... Read More

Singapore Clinical Trial: A two-part, First-In-Human, phase I, open-label, ascending dose study to assess safety and tolerability of DKB903 in participants with Rheumatoid Arthritis (RA) and participants with Systemic Lupus Erythematosus (SLE).

Singapore, Nov. 11 -- The Health Sciences Authority received information related to the study titled 'A two-part, First-In-Human, phase I, open-label, ascending dose study to assess safety and tolerab... Read More

• ««
• «
• 95
• 96
• 97
• 98
• 99
• 100